Dave Johnson Joins Biosplice Therapeutics Board of Directors
June 21 2021 - 9:15AM
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage
biotechnology company pioneering therapeutics based on alternative
pre-mRNA splicing for major diseases, announced today the addition
of Dave Johnson, most recently Founder and CEO of VelosBio, as an
independent director to its board.
“Mr. Johnson’s vast experience ushering drugs from pre-clinical
development through product launch will provide invaluable guidance
as we accelerate our oncology program, complete the clinical
development of lorecivivint, our knee osteoarthritis drug
candidate, and broaden the applicability of our alternative
splicing platform,” said Cevdet Samikoglu, CEO of Biosplice.
Dave Johnson brings more than 25 years of biopharmaceutical
experience. He most recently held the position as Founder and CEO
of VelosBio, a clinical-stage, oncology-focused biopharmaceutical
company advancing novel antibody-drug-conjugate and bispecific
antibody technologies, acquired by Merck for $2.75 billion. From
2013 to 2016, Mr. Johnson rose to Chief Executive Officer of Acerta
Pharma, an oncology-focused pharmaceutical company, where he
spearheaded acalabrutinib from early to late-stage global clinical
development. His term at Acerta concluded in an acquisition of the
company by AstraZeneca, a deal valued at up to $7 billion.
Earlier in his career, he held positions of increasing
responsibility at Calistoga (acq. by Gilead), Gloucester (acq. by
Celgene), Favrille, Millennium (acq. by Takeda), Immunex (acq. by
Amgen), and Hoffman-La Roche. Mr. Johnson also
currently serves as Chairman of Aura Biosciences, Inc. and as a
director of Zentalis Pharmaceuticals (NASDAQ: ZNTL).
Learn more about Biosplice’s Board of Directors at
https://www.biosplice.com/board-of-directors.
About BiospliceBiosplice is developing
first-in-class, small-molecule therapeutics based on pioneering
science of alternative pre-mRNA splicing. Stemming from
foundational discoveries in Wnt pathway modulation, Biosplice has
elucidated novel biology linking CLK/DYRK kinases to the
therapeutic regulation of alternative splicing. Alternative
splicing is an essential biological mechanism that regulates the
diversification of proteins in a cell, which, in turn, determines
cell type and function. Biosplice’s target class governs the
selection of tissue-specific mRNA splice sites, making them
attractive, druggable targets within the cellular “command and
control” center.
Biosplice’s drugs in clinical development include lorecivivint
for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers,
and a broad pipeline that ranges from Alzheimer’s disease to other
degenerative conditions. Learn more at
https://www.biosplice.com.
Corporate Contact: Erich HorsleyBiosplice
Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Apr 2024 to May 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From May 2023 to May 2024